Medications and glucose-6-phosphate dehydrogenase deficiency: An evidence-based review

Drug Safety

Volumn 33, Issue 9, 2010, Pages 713-726

  Youngster, Ilan ^a,b   Arcavi, Lidia ^c,d   Schechmaster, Renata ^c,d   Akayzen, Yulia ^a,b   Popliski, Hen ^a,b   Shimonov, Janna ^a,b   Beig, Svetlana ^a,b   Berkovitch, Matitiahu ^a,b  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c KAPLAN MEDICAL CENTER   (Israel)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Adverse drug reactions; Dapsone, adverse reactions; Genetic polymorphism; Glucosephosphate dehydrogenase deficiency; henazopyridine, adverse reactions; Methylthioninium chloride, adverse reactions; Nitrofurantoin, adverse reactions; Primaquine, adverse reactions; Rasburicase, adverse reactions; Tolonium chloride, adverse reactions

Indexed keywords

ACETANILIDE; ACETYLSALICYLIC ACID; CHLORAMPHENICOL; CHLOROQUINE; CHLORPROGUANIL; COTRIMOXAZOLE; DAPSONE; FURAZOLIDONE; GLIBENCLAMIDE; ISOBUTYL NITRITE; MEPACRINE; METHYLENE BLUE; NALIDIXIC ACID; NIRIDAZOLE; NITROFURANTOIN; PAMAQUINE; PHENACETIN; PHENAZOPYRIDINE; PHENYLHYDRAZINE; PRIMAQUINE; PROBENECID; RASBURICASE; SUCCIMER; SULFACETAMIDE; SULFAMETHOXAZOLE; SULFANILAMIDE; SULFAPYRIDINE; TOLONIUM CHLORIDE; UNINDEXED DRUG; URATE OXIDASE;

DRUG CONTRAINDICATION; DRUG INFORMATION; DRUG SAFETY; GENE MUTATION; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEMOLYSIS; HUMAN; PRIORITY JOURNAL; REVIEW;

ANEMIA, HEMOLYTIC; ANIMALS; EVIDENCE-BASED MEDICINE; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; HEMOLYSIS; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 77955567583     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11536520-000000000-00000     Document Type: Review

References (91)

1. Cappellini MD, Fiorelli G. Glucose-6-phosphate dehy-drogenase deficiency. Lancet 2008; 5: 64-74
2. Beutler E. G6PD deficiency. Blood 1994; 843: 613-636
3. Alving AS, Carson PE, Flanagan CL, et al. Enzymatic de-ficiency in primaquine-sensitive erythrocytes. Science 1956; 124: 484-485
4. Beutler E. The hemolytic effect of primaquine and relatedcompounds: a review. Blood 1959; 14: 103-139
5. Mason PJ. New insights into G6PD deficiency. Br J Hae-matol 1996; 94: 585-591
6. Burka ER. Infectious disease: a cause of hemolytic anemia inglucose-6 phosphate dehydrogenase deficiency. Ann Intern Med 1969; 70: 222-225
7. Beutler E. Glucose-6-phosphate dehydrogenase deficiency.N Engl J Med 1991; 324: 169-174
8. Lichtman MA, Beutler E, Kipps TJ, et al. Williams hema-tology. 7th ed. New York: McGraw-Hill, 2006
9. Kliegman RM, Behrman RE, Jenson HB, et al. Nelsontextbook of pediatrics. 18th ed. Philadelphia (PA): WB Saunders Co., 2007
10. Fauci AS, Braunwald E, Kasper DL, et al. Harrison's prin-ciples of internal medicine. 17th ed. New York: McGraw-Hill, 2008
11. Beutler E. Abnormalities of the hexose monophosphate shunt. Semin Hematol 1971; 8: 311-347
12. Rosen PJ, Johnson C, Mcgehee WG, et al. Failure ofmethylene blue treatment in toxic methemoglobinemia: association with glucose-6-phosphate dehydrogenase deficiency. Ann Intern Med 1971; 75: 83-86
13. Gauthier TW. Methylene blue-induced hyperbilirubinemiain neonatal glucose-6-phosphate dehydrogenase (G6PD) deficiency. J Matern Fetal Med 2000; 9: 252-254
14. Foltz LM, Dalal BI, Wadsworth LD, et al. Recognition andmanagement of methemoglobinemia and hemolysis in a G6PD-deficient patient on experimental anticancer drug Triapine. Am J Hematol 2006; 81: 210-211
15. Mandi G, Witte S, Meissner P, et al. Safety of the combi-nation of chloroquine and methylene blue in healthy adult men with G6PD deficiency from rural Burkina Faso. Trop Med Int Health 2005; 10: 32-38
16. Meissner PE, Mandi G, Witte S, et al. Safety of the methy-lene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso [ISRCTN27290841]. Malar J 2005; 4: 45
17. Chan TK, Todd D, Tso SC. Red cell survival studies inglucose-6-phosphate dehydrogenase deficiency. Bull Hong Kong Med Assoc 1974; 26: 41-48
18. Chan TK, Todd D, Tso SC. Drug-induced haemolysis inglucose-6-phosphate dehydrogenase deficiency. BMJ 1976; 2: 1227-1229
19. Lavelle KJ, Atkinson KF, Kleit SA. Hyperlactatemia andhemolysis in G6PD deficiency after nitrofurantoin inges-tion. Am J Med Sci 1976; 272: 201-204
20. Herman J, Ben-Meir S. Overt hemolysis in patients withglucose-6-phosphate dehydrogenase deficiency: a survey in general practice. Isr J Med Sci 1975; 11: 340-346
21. Powell RD, DeGowin RL, Alving AS. Nitrofurantoin-induced hemolysis. J Lab Clin Med 1963; 62: 1002-1003
22. Mercieca JE, Clarke MF, Phillips ME, et al. Acute haemo-lytic anaemia due to phenazopyridine hydrochloride in G-6-PD deficiency subject [letter]. Lancet 1982; II: 564
23. Tishler M, Abramov A. Phenazopyridine-induced hemolyticanemia in a patient with G6PD deficiency. Acta Haematol 1983; 70 (3): 208-209
24. Galun E, Oren R, Glikson M, et al. Phenazopyridine-induced hemolytic anemia in G-6-PD deficiency. Drug Intell Clin Pharm 1987; 21: 921-922
25. Jeffrey WH, Zelicoff AP, Hardy WR. Acquired methe-moglobinemia and hemolytic anemia after usual doses of phenazopyridine. Drug Intell Clin Pharm 1982; 16: 157-159
26. Noonan HM, Kimbrell M, Ben Johnson WB, et al. Phena-zopyridine-induced hemolytic anemia. Urology 1983; 21: 623-624
27. Nathan DM, Siegel AJ, Bunn HF. Acute methemoglobine-mia and hemolytic anemia with phenazopyridine: possible relation to acute renal failure. Arch Internal Med 1977; 137: 1636-1638
28. Fincher ME, Campbell HT. Methemoglobinemia and he-molytic anemia after phenazopyridine hydrochloride (pyr-idium) administration in end-stage renal disease. South Med J 1989; 82: 372-374
29. Charles LJ. Observations on the haemolytic effect of pri-maquine in 100 Ghanaian children. Ann Trop Med Para-sitol 1960; 54: 460-470
30. Greenberg MS, Wong H. Studies on the destruction of glu-tathione-unstable red blood cells: the influence of fava beans and primaquine upon such cells in vivo. J Lab Clin Med 1961; 57: 733-746
31. George JN, Sears DA, McCurdy PR, et al. Primaquinesensitivity in Caucasians: hemolytic reactions induced by primaquine in G-6-PD deficient subjects. J Lab Clin Med 1967; 70: 80-93
32. Krudsood S, Wilairatana P, Tangpukdee N, et al. Safetyand tolerability of elubaquine [bulaquine, CDRI 80/53] for treatment of Plasmodium vivax malaria in Thailand. Korean J Parasitol 2006; 44: 221-228
33. Degowin RL, Eppes RB, Powel RD, et al. The haemolyticeffects of diaphenylsulfone [DDS] in normal subjects and in those with glucose-6-phosphate- dehydrogenase deficiency. Bull WHO 1966; 35: 165-179
34. Grossman S, Budinsky R, Jollow D. Dapsone-induced he-molytic anemia: role of glucose-6-phosphate dehydrogen-ase in the hemolytic response of rat erythrocytes to N-hydroxydapsone. J Pharmacol Exp Ther 1995; 273: 870-877
35. Sheehy TW. Supplemental sulfone (dapsone) therapy: use intreatment of chloroquine-resistant falciparum malaria. Arch Intern Med 1967; 119: 561-566
36. Fanello CI, Karema C, Avellino P, et al. High risk of severeanaemia after chlorproguanil-dapsone+artesunate anti-malarial treatment in patients with G6PD [A-] deficiency. PLoS ONE 2008; 3: e4031
37. Brant JM. Rasburicase: an innovative new treatmentfor hyperuricemia associated with tumor lysis syndrome. J Oncol Nurs 2002; 6: 12-16
38. Browning LA, Kruse JA. Hemolysis and methemoglobine-mia secondary to Rasburicase administration. Ann Pharmacother 2005; 39: 1932-1935
39. Marquez A, Todd M. Acute hemolytic anemia and agranu-locytosis following intravenous administration of toluidine blue. Am Pract Dig Treat 1959; 10: 1548-1550
40. Teunis BS, Leftwich EI, Pierce LE. Acute methemoglobi-nemia and hemolytic anemia due to toluidine blue. Arch Surg 1970; 101: 527-531
41. Cottafava F, Nieri S, Franzone G, et al. Double blind trialbetween placebo and paracetamol in children with G6PD deficiency. Ped Med Chir 1990; 12: 631-842.
42. Sklar GE. Hemolysis as a potential complication of aceta-minophen overdose in a patient with glucose-6-phosphate dehydrogenase deficiency. Pharmacotherapy 2002; 22: 656-658
43. Wright RO, Perry HE, Shannon NW. Hemolysis afteracetaminophen overdose in a patient with glucose-6-phosphate dehydrogenase deficiency. J Toxicol Clin Tox-icol 1996; 34: 731-734
44. Walz B, Riecken B. A young man with acute generalizedjaundice and intermittent epigastric pain [abstract]. Dtsch Med Wochenschr 2008; 133: 129-132
45. Shahidi NT, Westring DW. Acetylsalicylic acid-inducedhemolysis and its mechanism. J Clin Invest 1970; 49: 1334-1340
46. Glader BE. Evaluation of hemolytic role of aspirin inglucose-6-phosphate dehydrogenase deficiency. J Pediatr 1976; 89: 1027-1028
47. 2] challenge. Pediatr Res 1978; 12: 927-931
48. Shalev O. Long-term low-dose aspirin is safe in glucose-6-phosphate dehydrogenase deficiency. DICP 1991; 25: 1074-1075
49. Kanetaka T, Oda T. Toxic liver injuries. Acta Pathol Jpn1973; 23:617-627
50. Prankerd TAJ. Hemolytic effects of drugs and chemicalagents. Clin Pharmacol Ther 1963; 4: 334-350
51. Campbell GD, Steinberg MH, Bower JD. Ascorbic acid in-duced hemolysis in G6PD deficiency [letter]. Ann Intern Med 1975; 82: 810
52. Udomratn T, Steinberg MH, Campbell Jr GD, et al. Effectsof ascorbic acid on glucose-6-phosphate dehydrogenase-deficient erythrocytes: studies in an animal model. Blood 1977; 49: 471-475
53. Barkshi S, Singh J. Acute hemolytic anemia in typhoid fever.Indian J Pediatr 1972; 39: 270-273
54. McCaffrey RP, Halsted CH, Wahab MFA, et al. Chlor-amphenicol induced hemolysis in Caucasian glucose-6-phosphate dehydrogenase deficiency. Ann Intern Med 1971; 74: 722-726
55. Rajkondawar VL, Modi TH, Mishra SN. Drug inducedacute haemolytic anaemia in glucose-6-phosphate dehy-drogenase deficiency subjects. J Assoc Physicians India 1968; 16: 589-593
56. Chan TK, Chesterman CN, McFadzean AJ, et al. Thesurvival of glucose-6-phosphate dehydrogenase-deficient erythrocytes in patients with typhoid fever on chlor-amphenicol therapy. J Lab Med 1971; 77: 177-184
57. Choudhry VP, Ghafary A, Zaher M, et al. Drug-inducedhaemolysis and renal failure in children with glucose-6-phosphate dehydrogenase deficiency in Afghanistan [abstract]. Ann Trop Paediatr 1990; 10: 335-338
58. Gaetani GD, Mareni C, Ravazzolo R, et al. Haemolyticeffect of two sulphonamides evaluated by a new method. Br J Haematol 1976; 32: 183-191
59. Gerr F, Frumkin H, Hodgins P. Hemolytic anemia follow-ing succimer administration in glucose-6-phosphate dehy-drogenase deficient patient. Clin Toxicol 1994; 32 (5): 569-575
60. Graziano JH, Lolacono NJ, Moulton T, et al. Controlledstudy of meso-2,3-dimercaptosuccinic acid for the management of childhood lead intoxication. J Pediatr 1992; 120: 133-139
61. Abbate SL, Hoogwerf BJ. Hemolytic anemia associatedwith sulfonylurea use. Diabetes Care 1990; 13: 904-905
62. Meloni G, Meloni T. Glyburide-induced acute hemolysis ina G6PD-deficient patient with NIDDM. Br J Haematol 1996 Jan; 92: 159-160
63. Vinizo S, Andres E, Perrin AE, et al. Glibenclamide-inducedacute hemolytic anemia revealing a G6PD-deficiency. Diabetes Res Clin Pract 2004; 64: 181-183
64. Product information: oral tablets, glyburide oral tablets.New York: Pharmacia & Upjohn Company, 200965. McCurdy PR, Donohoe RF. Pyridoxine-responsive anemiaconditioned by isonicotinic acid hydrazide. Blood 1966; 27: 352-362
65. Aderka D, Garfinkel D, Bograd H, et al. Isosorbide dini-trate-induced hemolysis in G6PD-deficient subjects. Acuta Haemat 1983; 69: 63-64
66. Mandal BK, Stevenson J. Hemolytic crisis caused by nali-dixic acid [letter]. Lancet 1970; I: 614
67. Belton EM, Jones RV. Hemolytic anemia due to nalidixicacid [letter]. Lancet 1965; II: 691
68. Oh YR, Carr-Lopez SM, Probasco JM, et al. Levofloxacin-induced autoimmune hemolytic anemia. Ann Pharma-cother 2003; 37: 1010-1013
69. Lim S, Alam MG. Ciprofloxacin-induced acute interstitialnephritis and autoimmune hemolytic anemia. Ren Fail 2003; 25: 647-651
70. Carmoi T, Bordier L, Bonnefoy S, et al. Ofloxacin is con-traindicated in case of G6PD deficiency: is it evidenced based? Rev Med Intern 2009; 30: 355-357
71. Product information: ciprofloxacin hydrochloride oraltablets. Wayne (NJ): Bayer HealthCare Pharmaceuticals Inc, 2009
72. Dern RJ, Beutler E, Alving AS. The hemolytic effect ofprimaquine. J Lab Clin Med 1955; 45: 30-39
73. Wood Jr WB. Anemia during sulfanilamide therapy. JAMA1938; 11: 1916-1919
74. Wintrobe M. Clinical hematology. Philadelphia (PA): Lea &Febringer, 1951: 434
75. Szeinberg A, Pras M, Sheba C, et al. The hemolytic effectof various sulfonamides on subjects with a deficiency of glucose-6-phosphate dehydrogenase of erythrocytes. Isr J Med Sci 1959; 18: 176
76. Cohen SM, Rosenthal DS, Karp PJ. Ulcerative colitisand erythrocyte G6PD deficiency: salicylazosulfapyridine-provoked hemolysis. JAMA 1968; 205: 528-530
77. Kaplinsky N, Frankl O. Salicylazosulphapyridine-inducedHeinz body anemia. Acta Haematol 1978; 59: 310-314
78. Markowitz N, Saravolatz LD. Use of trimethoprim-sulfa-methoxazole in a glucose-6-phosphate dehydrogenase deficient population. Rev Infect Dis 1987; 9 Suppl. 2: S218-25
79. Chan TK, McFadzean JS. Hemolytic effect of trimetho-prim-sulfamethoxazole in G6PD deficiency. Trans R Soc Trop Med Hyg 1974; 68: 61-62
80. Shinohara K, Tanaka KR. The effects of adriamycin(doxorubicin HCl) on human red blood cells. Hemoglobin 1980; 4: 735-745
81. Gaetani G, Salvidio E, Pannacciulli I, et al. Absence of he-molytic effects of L-DOPA on transfused G6PD-deficient erythrocytes. Experientia 1970; 26: 785-786
82. Sansone G, Reali S, Sansone R, et al. Acute hemolytic ane-mia induced by a pyrazolonic drug in a child with glucose-6-phosphate dehydrogenase deficiency. Acta Haematol 1984; 72: 285-287
83. Khoo KK. The treatment of malaria in glucose-6-phosphatedehydrogenase deficient patients in Sabah [abstract]. Ann Trop Med 1981; 75: 591-595
84. Heinrich RA, Smith TC, Buchaman RA. A pharmacologicalstudy of a new sulfonamide in glucose-6-phosphate dehy-drogenase deficient subjects. J Clin Pharmacol 1971 Nov-Dec; 11 (6): 428-432
85. Eldad A, Neuman A, Weinberg A, et al. Silver sulphadiazine-induced hemolytic anemia in a glucose-6-phosphate dehy-drogenase-deficient burn patient. Burns 1991; 17: 430-432
86. Brown AK, Cevik N. Hemolysis and jaundice in the new-born following maternal treatment with sulfamethoxypyr-idazine (kynex). Pediatrics 1965; 36: 742-744
87. Kellermeyer RW, Tarlov AR, Schrier SL, et al. Hemolyticeffect of commonly used drugs on erythrocytes deficient in glucose-6-phosphate dehydrogenase. J Lab Clin Med 1958; 52: 827-828
88. Mela Q, Perpignano G, Ruggiero V, et al. Tolerabilityof tiaprofenic acid in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Drugs 1988; 35 Suppl. 1: 107-110
89. Zail SS, Charlton RW, Bothwell TH. The haemolytic effectof certain drugs in Bantu subjects with a deficiency of glucose-6-phosphate dehydrogenase. S Afr J Med Sci 1962; 27: 95-99
90. Zinkham W. Peripheral blood and bilirubin values in nor-mal full-term primaquine-sensitive Negro infants: effect of vitamin K. Pediatrics 1963; 31: 983-995
91. Kulwichit W, Torranin P. Glucose-6-phosphate dehy-drogenase deficiency, vitamin K, and ambiguity in medical textbooks. Acta Haematol 2004; 111: 173-174